Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micro-dosing versus standard transfer from methadone to buprenorphine for opioid dependence
ACTRN12622000444785Phase 4Completed
- Sponsor
- Royal Prince Alfred Hospital
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of buprenorphine and methadone in opioid use disorder (OUD) (2 arms), sponsored by Royal Prince Alfred Hospital. Primary endpoint: Success of transfer. Started May 2021; status: completed.
02
Drugs
buprenorphinemethadone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on ACTRN12622000444785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000444785.